Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT-EHA CAR-T 2019 | CD123 CAR-T therapy for the treatment of AML

Elizabeth Budde • 8 Mar 2019
EBMT-EHA CAR-T 2019
Acute Myeloid Leukemia Leukemia CAR-T

Elizabeth Budde, MD, PhD City of Hope National Medical Center, Duarte, CA, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA) and discusses the results of a recent trial investigating CD123 CAR T-cell therapy for relapsed/refractory acute myeloid leukemia.

More from Elizabeth Budde

The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL 18:55
The use of bispecific antibodies and other immunotherapeutics in early lines of treatment for NHL
Elizabeth Budde et al. • 28 Sep 2025
Phase II study of subcutaneous mosunetuzumab + polatuzumab vedotin in post-BTK inhibitor R/R MCL 3:41
Phase II study of subcutaneous mosunetuzumab + polatuzumab vedotin in post-BTK inhibitor R/R MCL
Elizabeth Budde • 20 Jun 2025
Interim results from the MorningSun study: mosunetuzumab for high-tumor burden FL 2:50
Interim results from the MorningSun study: mosunetuzumab for high-tumor burden FL
Elizabeth Budde • 20 Jun 2025
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy 12:30
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
Elizabeth Budde et al. • 13 Apr 2025

Related Videos

The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL 1:41
The safety and efficacy of rapcabtagene autoleucel in adult patients with R/R B-ALL
Pere Barba • 7 Dec 2025
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia 1:48
Targeting mitochondrial metabolism with EB2023 to overcome venetoclax resistance in acute leukemia
Michael Savona • 6 Dec 2025
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML 1:31
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen • 6 Dec 2025
The development and international validation of an unsupervised classification model in AML 1:28
The development and international validation of an unsupervised classification model in AML
Amin Turki • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals